Clairity raised $43 million to expand its AI mammography tool for predicting five-year breast cancer risk.
Key Details
- 1Clairity, founded in 2020 by Dr. Constance Lehman of Mass General, focuses on AI for breast cancer risk assessment.
- 2The company secured $43 million in Series B funding led by Ace Global Equity and Santé Ventures, with support from the Breast Cancer Research Foundation.
- 3Clairity Breast is the first AI tool to predict five-year breast cancer risk from standard mammograms.
- 4The product received FDA de novo authorization in May 2024.
- 5New funds will support commercialization and partnership expansion.
Why It Matters
Clairity's advancements could lead to earlier detection and prevention strategies using existing mammography infrastructure, potentially improving patient outcomes. The funding and FDA approval mark important milestones for AI adoption in radiology.
Source
Radiology Business
Related News
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
•Radiology Business
NYC Health + Hospitals CEO Considers AI to Replace Radiologists
NYC Health + Hospitals CEO suggests AI could partially replace radiologists, pending regulatory approval.
•AuntMinnie
AI Models Reveal Racial Disparities in Breast Cancer Patterns
Machine learning models reveal significant racial disparities and key predictors in breast cancer incidence across diverse groups.